• Weiming Weng, Shengquan He, Guoxiong Zhang, Xindong Zhou, Kang Li, and Jiajun Lai.
• Department of Gastrointestinal Surgery, The Yue Bei People's Hospital of Shaoguan, No. 133, Huimin South Road, Shaoguan, Guangdong 512026, China.
• Clinics (Sao Paulo). 2024 Jan 1; 79: 100516100516.

ObjectiveColorectal cancer is one of the most common malignant tumors in the world, which seriously threatens human health. It is essential for the search for new oncogene targets in colorectal cancer.MethodsSamples from 57 colorectal cancer patients were collected in this study. Next-Generation Sequencing (NGS) was performed to detect gene mutation, assess Microsatellite Instability (MSI), and evaluate Tumor Mutational Burden (TMB). RNA data from 528 CRC patients from the TCGA database were analyzed.ResultsA total of 57 colon cancer patients were included in this study, including 30 males and 27 females, with a mean age of 56 years. In this study, the most common mutations were APC (79 %), TP53 (61 %), TTN (48 %), KRAS (42 %), SYNE1 (28 %), MUC16 (25 %), PIK3CA (25 %), FAT4 (22 %), RYR2 (19 %), OBSCN (18 %), and ZFHX4 (18 %). Subsequently, the authors analyzed gene mutations in colorectal cancer patients according to gender, age, and TMB status. Significant differences in immune cell infiltration were found between colorectal cancer tissues and normal tissues by CIBERSORT analysis. LRP1B may serve as a potential colorectal cancer therapeutic target, and its absence leads to changes in immune cell infiltration.ConclusionThe authors described the molecular characteristics of CRC. Loss of LRP1B leads to changes in immune cell infiltration and can be used as a therapeutic target for colorectal cancer.Copyright © 2024. Published by Elsevier España, S.L.U.

27 keywords...

hide…